Related Experiment Video
Updated: Jul 4, 2026

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report
Jennifer B Merriman1, Juan M Gonzalez, Jack Rychik
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. jmerriman@obgyn.upenn.edu
Background:
Neonatal survival and prognosis are closely linked with development of hydrops in cases of sustained fetal tachycardia. Several antiarrhythmic medications are available for conversion to sinus rhythm.
Case:
An 18-year-old woman had an audible fetal arrhythmia at 25 weeks' gestation. Fetal echocardiography revealed supraventricular tachycardia with worsening cardiac function at 28 weeks. Digoxin therapy was initiated and sotalol was later added for new-onset hydrops. The medications were then adjusted, and the fetus' heart rate converted to sinus rhythm with resolution of the hydrops. The patient was then managed as an outpatient with antenatal testing, serial laboratory studies and electrocardiograms until 39 weeks.
Conclusion:
Digoxin and sotalol therapy can be successful in blocking likely nodal reentry in sustained fetal supraventricular tachycardia, thus allowing resolution of hydrops with a favorable outcome.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiomyopathy III: Hypertrophic Cardiomyopathy
